Clinical practice. Today's understanding of the haemolytic uraemic syndrome.
The haemolytic uraemic syndrome (HUS) includes the triad of haemolytic anaemia, thrombocytopenia, and acute renal failure. The classical form [D(+) HUS] is caused by infectious agents, and it is a common cause of acute renal failure in children. The enterohaemorrhagic Escherichia coli-producing Shiga toxin (Stx) is the most common infectious agent causing HUS. Other infectious agents are Shigella and Streptococcus pneumoniae. Infections by S. pneumoniae can be particularly severe and has a higher acute mortality and a higher long-term morbidity compared to HUS by Stx. Atypical HUS [D(-)Stx(-)HUS] are often used by paediatricians to indicate a presentation of HUS without preceding diarrhoea. Almost all patients with D(-)Stx(-)HUS have a defect in the alternative pathway, for example, mutations in the genes for complement factor H, factor I, and membrane co-factor protein. Mutations in the factor H gene are described more often. The majority of children with D(+) HUS develop some degree of renal insufficiency, and approximately two thirds of children with HUS will require dialysis therapy, while about one third will have milder renal involvement without the need for dialysis therapy. General management of acute renal failure includes appropriate fluid and electrolyte management, antihypertensive therapy, and the initiation of renal replacement therapy when appropriate. Specific management issues in HUS include management of the haematological complications of HUS, monitoring for extra-renal involvement, avoiding antidiarrhoeal drugs, and possibly avoiding of antibiotic therapy. In addition to the obligatory supportive treatment and tight control of hypertension, there is anecdotal evidence that plasma therapy may induce remission and, in some cases, maintain it. Fresh frozen plasma contains factor H at physiological concentrations. A new therapy for D(-)Stx(-)HUS is a humanised monoclonal antibody (Eculizumab) that blocks complement activity by cleavage of the complement protein C5. It prevents the generation of the inflammatory peptide C5a and the cytotoxic membrane-attack complex C5b-9. We have first positive results, but it is still not approved for HUS.
Scheiring
Johanna
J
Department of Paediatrics, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria.
Rosales
Alejandra
A
Zimmerhackl
Lothar Bernd
LB
D058186:Acute Kidney Injury / Q000209:etiology* / Q000517:prevention & control; D002648:Child; D003165:Complement System Proteins / Q000378:metabolism*; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000150:complications / Q000628:therapy; D006801:Humans; D011379:Prognosis; D017582:Renal Replacement Therapy / Q000379:methods*
D003165:Complement System Proteins
J Med Genet. 2004 Jun;41(6):e84
15173250
J Infect Dis. 1985 May;151(5):775-82
3886804
N Engl J Med. 2009 Jan 29;360(5):542-4
19179328
Pediatr Nephrol. 2008 Oct;23(10):1749-60
18704506
Infect Immun. 2005 Aug;73(8):4607-13
16040972
Pediatr Nephrol. 2007 Jan;22(1):10-6
17058051
Expert Rev Anti Infect Ther. 2008 Feb;6(1):101-8
18251667
Clin Exp Immunol. 2008 Jan;151(1):1-13
18081690
Pediatrics. 1998 Apr;101(4 Pt 1):699-703
9521959
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12966-71
14566051
J Pediatr. 1998 Aug;133(2):220-3
9709709
Pediatr Nephrol. 2009 Apr;24(4):687-96
18800230
Blood. 2008 Dec 15;112(13):4948-52
18796626
Pediatr Nephrol. 2003 Sep;18(9):952-5
12836093
Semin Thromb Hemost. 2006 Mar;32(2):113-20
16575686
Mol Immunol. 2006 Jan;43(1-2):97-106
16026839
Schweiz Med Wochenschr. 1955 Sep 20;85(38-39):905-9
13274004
N Engl J Med. 1995 Aug 10;333(6):364-8
7609755
Springer Semin Immunopathol. 2005 Nov;27(3):359-74
16189652
Pediatr Nephrol. 2001 Apr;16(4):362-5
11354782
Infect Immun. 2002 Feb;70(2):612-9
11796590
J Thromb Thrombolysis. 2001 May;11(3):261-72
11577265
J Am Soc Nephrol. 2005 Apr;16(4):1035-50
15728781
J Nephrol. 1998 Nov-Dec;11(6):300-10
10048496
Pediatrics. 2000 Feb;105(2):462-3
10691516
Pediatrics. 2002 Aug;110(2 Pt 1):371-6
12165593
Lancet. 2005 Mar 19-25;365(9464):1073-86
15781103
N Engl J Med. 2000 Jun 29;342(26):1990-1
10874069
Artif Organs. 1995 Jun;19(6):506-10
8526789
Br Med Bull. 2006;77-78:5-22
16968692
Pediatr Nephrol. 2004 Mar;19(3):317-21
14714171
J Immunol. 2002 Jun 15;168(12):6298-304
12055245
Trends Immunol. 2001 Jul;22(7):345-8
11429311
Semin Thromb Hemost. 2006 Mar;32(2):121-7
16575687
Clin Exp Immunol. 2008 Feb;151(2):199-209
18070148
Pediatr Nephrol. 2003 Nov;18(11):1095-101
13680331
Infection. 1999 Nov-Dec;27(6):341-7
10624594
Pediatr Nephrol. 2004 Jun;19(6):688-90
15064939
Clin Infect Dis. 2008 Apr 15;46(8):1197-9
18444855
Kidney Int. 2001 Sep;60(3):831-46
11532079
Pediatr Nephrol. 2000 Jan;14(1):73-83
10654337
J Am Soc Nephrol. 2005 Jul;16(7):2150-5
15917334